Downregulation of trefoil factor-3 expression in the rectum is associated with the development of ulcerative colitis-associated cancer

Streptococcus Thermophilus UASt-09 Upregulates Goblet Cell Activity in Colonic Epithelial Cells to a Greater Degree than other Probiotic Strains

Probiotics have been widely used in maintaining gastrointestinal health, despite their actual mechanism remaining obscure. There are several hypotheses behind the beneficial effects of probiotics including the regulation of intestinal barrier function and improvement in immune responses in the gastrointestinal system. Multiple probiotics have been introduced in the market as effective dietary supplements in improving gastrointestinal integrity, but there are no or few studies that demonstrate their underlying mechanism. In the current study, we investigated and compared the efficacy of four probiotics (based on different bacterial species) in refining gastrointestinal health by improving mucus biosynthesis and intestinal immune response under in-vitro conditions. By analyzing the gene expression of mucus biosynthesis and intestinal immune response markers, we found that probiotic Streptococcus thermophilus UASt-09 showed promising potential in refining mucosal barrier and gastrointestinal health in human colonic epithelial cells, as compared to other commercial probiotics.

Efficacy and mechanism of Hudi enteric-coated capsules combined with beclomethasone dipropionate enema in treatment of active ulcerative colitis

BACKGROUND

Ulcerative colitis (UC) is a clinically common chronic intestinal disease with a high incidence. The clinical treatment of UC is mainly based on glucocorticoid drugs, but due to the recurrence of UC, the treatment effect is not satisfactory. Hudi enteric-coated capsules have the effect of clearing heat and cooling blood, and may have a positive effect in the treatment of UC.

AIM

To investigate the efficacy and mechanism of Hudi enteric-coated capsules combined with beclomethasone dipropionate enema in the treatment of active UC.

METHODS

Using the random number table method, 106 patients with active UC who were treated at our hospital from January 2018 to October 2019 were divided into a control group (53 cases) and a study group (53 cases). The control group was treated with beclomethasone dipropionate enema alone, and the study group was treated with Hudi enteric-coated capsules plus beclomethasone dipropionate enema. The clinical curative effect, traditional Chinese medicine syndrome score, inflammatory factor levels, inducible nitric oxide synthase (iNOS) expression in the colonic mucosa, and immune function were compared between the two groups.

RESULTS

The total effective rate in the study group was significantly higher than that in the control group (92.45% vs 77.36%, P < 0.05). The total syndrome score, CD3⁺ T lymphocytes, CD4⁺ T lymphocytes, and CD4⁺/CD8⁺ T lymphocyte ratio in the study group were significantly higher than those in the control group, but the levels of interleukin-6, interleukin-8, tumor necrosis factor-α, and iNOS expression in the colonic mucosa were significantly lower than those of the control group (P < 0.05).

CONCLUSION

Hudi enteric-coated capsules combined with beclomethasone dipropionate enema is effective in the treatment of active UC, which can significantly relieve clinical symptoms, reduce the body's inflammatory response, adjust the level of iNOS in the colonic mucosa, and improve immune function.

Extracellular production of recombinant sus scrofa trefoil factor 3 by Brevibacillus choshinensis

Trefoil factor 3 (TFF3) is involved in cell adhesion, motility and apoptosis, regulates mucosal immunity and maintains the functional integrity of intestinal epithelia. The upregulation of TFF3 expression in the weaning rat intestine attracted our interest. The present study hypothesized that TFF3 may serve a role in preventing diarrhea in weaning piglets, which is an important consideration in the pig farming industry. Previous recombinant TFF3 protein expression yields obtained from Escherichia coli were too low and the bioactivity of the protein was poor. Hence, this expression system was unsuitable for industrial applications. The present study explored the production of recombinant sus scrofa TFF3 in a Brevibacillus choshinensis (B. choshinensis) expression system, aiming to enhance the expression level of bioactive protein. To achieve this, the sus scrofa TFF3-encoding gene fragment was fused into an E. coli-Brevibacillus shuttle vector pNCMO2. High levels of TFF3 (30 mg/l) were produced and secreted into the B. choshinensis culture medium in soluble form with a molecular mass of 13.6 kDa and high immunoreactivity in western blotting. Thus, Brevibacillus may be used to produce useful mucosal factors for biochemical analyses and mucosal protection, and in industrial applications to produce novel inhibitors of diarrhea.

The Long Non-Coding RNA ENST00000489676 Influences Papillary Thyroid Cancer Cell Proliferation and Invasion through Regulating MiR-922

Purpose: Long noncoding RNAs (lncRNAs) have been reported to be associated with the growth and progression of numerous cancers. The aim of this study was to explore the potential function and molecular mechanism of lncRNA ENST00000489676 in the proliferation and invasion of papillary thyroid cancer (PTC). Methods: QRT-PCR (quantitative reverse transcriptase-polymerase chain reaction) was used to determine the levels of ENST00000489676. CCK-8 (Cell Counting Kit-8) assay and colony formation assay were performed to detect the cell proliferation. Flow cytometry was used to analyze the cell cycle. Transwell and scratch assay were performed to detect the migration and invasion ability. Results: The expression of ENST00000489676 was significantly overexpressed in TPC1 compared to KTC1 cell lines. When ENST00000489676 expression was knocked down, the proliferation, migration and invasion ability as well as cell cycle were all promoted in PTC cell lines, while those abilities were all suppressed when ENST00000489676 overexpressed. Overexpression of ENST00000489676 could inhibit cell proliferation, migration and invasion in vitro. Moreover, ENST00000489676 may mediate tumor suppression in PTC cells through suppressing miR-922. Conclusions: ENST00000489676 negatively regulated the proliferation, migration invasion and cell cycle of PTC. The overexpression of ENST00000489676 inhibited the progression of PTC through suppressing miR-922. ENST00000489676 could be act as a novel diagnosis marker and a potential therapeutic target for PTC.

Intestinal enteroids/organoids: A novel platform for drug discovery in inflammatory bowel diseases

The introduction of biologics such as anti-tumor necrosis factor (TNF) monoclonal antibodies followed by anti-integrins has dramatically changed the therapeutic paradigm of inflammatory bowel diseases (IBD). Furthermore, a newly developed anti-p40 subunit of interleukin (IL)-12 and IL-23 (ustekinumab) has been recently approved in the United States for patients with moderate to severe Crohn’s disease who have failed treatment with anti-TNFs. However, these immunosuppressive therapeutics which focus on anti-inflammatory mechanisms or immune cells still fail to achieve long-term remission in a significant percentage of patients. This strongly underlines the need to identify novel treatment targets beyond immune suppression to treat IBD. Recent studies have revealed the critical role of intestinal epithelial cells (IECs) in the pathogenesis of IBD. Physical, biochemical and immunologic driven barrier dysfunctions of epithelial cells contribute to the development of IBD. In addition, the recent establishment of adult stem cell-derived intestinal enteroid/organoid culture technology has allowed an exciting opportunity to study human IECs comprising all normal epithelial cells. This long-term epithelial culture model can be generated from endoscopic biopsies or surgical resections and recapitulates the tissue of origin, representing a promising platform for novel drug discovery in IBD. This review describes the advantages of intestinal enteroids/organoids as a research tool for intestinal diseases, introduces studies with these models in IBD, and gives a description of the current status of therapeutic approaches in IBD. Finally, we provide an overview of the current endeavors to identify a novel drug target for IBD therapy based on studies with human enteroids/organoids and describe the challenges in using enteroids/organoids as an IBD model.